[Chromosomal aberrations induced by thio-TEPA in cells of malignant ovarian tumors in humans].
Chromosome abberations in cells of 4 ovarian cancer patients have been studied prior to and during the treatment with ThioTEPA. ThioTEPA was injected intraperitoneally once a week in a dose of 40 mg. The amount of abberant cells prior to the therapy averaged 7.8%. 14 days following the treatment the amount of cells with chromosome abberations reached its peak (88.6%). By the 21st day of ThioTEPA treatment, when a total dose of the drug was 120 mg, the number of cells with abberations rapidly decreased, and by the 28-35th day of treatment there was a fall up to the initial values. ThioTEPA induced in tumor cells chiefly abberations of chromatoid type that evidenced the injury of cells in a phase G2 of the cellular cycle. A decrease in the number of chromosome abberations in tumor cells during the treatment with chemotherapeutic drugs is a morphological indication of the appearance of drug resistance.
D002869:Chromosome Aberrations; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics; D013852:Thiotepa / Q000627:therapeutic use*
D013852:Thiotepa
Khromosomnye aberratsii, vyzvannye tioTEF v kletkakh zlokachestvennykh opukholeĭ iaichnikov cheloveka